A director at AP (Thailand) PLC sold 100,000 shares at 7.950THB and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
AP saw yoy and qoq improvements in 1Q25 presales, mainly driven by low-rise presales, reflecting resilient demand especially in the mid- to high-end segment and its position as a market leader. 1Q25 earnings are expected to be flat yoy but decline qoq, due to margin compression and fewer condos being transferred during the period. We remain optimistic about 2025 as the company is expected to benefit from real estate stimulus measures. Maintain BUY. Target price: Bt11.30.
KEY HIGHLIGHTS Strategy 1H25 Potential Treasury Buyback Target A significant number of companies participated in the buyback programme in 2025. We expect HANA, PTTEP, KTB, and BH to be potential buyback targets in 1H25. Update AP Thailand (AP TB/BUY/Bt7.60/Target: Bt11.30) Delivers strong presales in 1Q25; remains optimistic about its outlook in 2025.
GREATER CHINA Update Hong Kong Exchanges and Clearing (388 HK/BUY/HK$328.40/Target: HK$394.00): Expecting solid 1Q25 earnings growth but trade war risk lingers. INDONESIA Sector Mining: The gold game: Key beneficiaries of the bull run. MALAYSIA Malaysia Gems Conference Highlights Alliance Bank Malaysia (ABMB MK/HOLD/RM4.35/Target: RM4.84): Loan growth outpaces industry but rights issue caps upside. Maintain HOLD and target price of RM4.84. ITMAX Systems (ITMAX MK/BUY/RM3.72/Target: RM4.30): Ex...
GREATER CHINA Results COSCO SHIPPING Ports (1199 HK/BUY/HK$4.78/Target: HK$5.90) 2024: Core earnings in line; expect low single digit throughput growth in 2025. CSPC Innovation Pharmaceutical Co (300765 CH/BUY/Rmb37.00/Target: Rmb50.00) 2024: Smooth progress in R&D promises bright long-term outlook. Hansoh Pharmaceutical Group Company (3692 HK/BUY/HK$20.10/Target:HK$29.00) 2024: Results beat; strong growth momentum continues. Meituan (3690 HK/BUY/HK$167.60/Target: HK$216.00) ...
GREATER CHINA Initiate Coverage JBM Healthcare (2161 HK/BUY/HK$1.82/Target: HK$2.42) Revitalising iconic pharma heritage brands. Results Wharf Real Estate Investment Co (1997 HK/BUY/HK$20.55/Target: HK$23.10) 2024: Underlying net profit met expectation; lower finance costs being key driver of profits amid top-line uncertainties. Update Jiumaojiu International Holdings (9922 HK/HOLD/HK$3.08/Target: HK$3.00) ...
AP reported a net profit of Bt1.29b in 4Q24 (-3% yoy, -11% qoq), in line with market expectations. AP has set an aggressive strategy for 2025, highlighting its resilience and strong fundamentals. As a mid- to high-end specialist, AP stands to benefit from potential LTV easing. The dividend yield of 6.9% should also support its share price. Maintain BUY. Target price: Bt11.30.
Results Amata Corporation (AMATA TB/BUY/Bt23.90/Target: Bt35.00) 4Q24: Net income misses expectations but still robust yoy and qoq. AP Thailand (AP TB/BUY/Bt8.70/Target: Bt11.30) 4Q24: Earnings in line; aggressive strategy for 2025. Bumrungrad Hospital (BH TB/BUY/Bt183.50/Target: Bt232.00) 4Q24: Strong 4Q24 earnings attributable to tax benefit. Hana Microelectronics (HANA TB/HOLD/Bt20.10/Target: Bt22.00) 4Q24: Net loss from high impairment. Indorama Ventures (IVL TB/BUY/Bt19.30/Target: Bt30.00)...
GREATER CHINA Sector Automobile Weekly: PV sales picked up wow while the wait-and-see sentiment continues. Upgrade Li Auto and XPeng from HOLD to BUY and raise target price to HK$156.00 and HK$110.00 respectively. Maintain MARKET WEIGHT on the sector. Top BUYs: Geely, CATL, Fuyao and Desay. Results BeiGene (6160 HK/BUY/HK$161.60/Target: HK$220.00) 2024: Results beat; targets operating profit...
GREATER CHINA Sector Internet Growth potential and AI development trends following emergence of DeepSeek. Property Policy implementation and development remain the key focus and catalyst. INDONESIA Strategy Catching A Falling Knife Or Opportunity To Buy? We Say Buy Our picks are BBCA, BBTN, CMRY, ICBP, KLBF, CTRA, AMRT, PGEO, TL...
Summary Sansiri Public Co Ltd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Sansiri Public Co Ltd (Sansiri) carries out property development and real estate services. Its main activities include the development and sale of residential properties such as single-detached ho...
AP reported a net profit of Bt1.45b in 3Q24 (-15% yoy, +14% qoq). The results were in line with expectations. 10M24 presales accounted for 71% of its full-year target. While reaching the full-year target may be challenging, we anticipate that total presales in 2024 will come close to the previous year. 4Q24 earnings are expected to remain stable qoq, underpinned by existing projects and backlogs. We still like AP for fundamentals and undemanding valuation. Maintain BUY. Target price: Bt11.30.
KEY HIGHLIGHTS Results AP Thailand (AP TB/BUY/Bt8.60/Target: Bt11.30) 3Q24: Results meet expectations; strong backlog supports 4Q24 earnings. Bangkok Dusit Medical Services (BDMS TB/BUY/Bt26.50/Target: Bt33.00) 3Q24: Record-high earnings delivered. BTG TB (BTG TB/BUY/Bt20.10/Target: Bt24.20) 3Q24: Earnings in line. GFPT (GFPT TB/BUY/Bt10.80/Target: Bt13.00) 3Q24: Earnings in line; strong 4Q24 ea...
The SETPROP index outperformed the SET index, gaining 15% vs the latter’s 10% increase. However, we maintain a cautious view on the residential market, with conditions expected to remain unchanged in 2H24. High interest rates and tightening banking policies continue to pose challenges to the sector. We recommend a selective BUY − AP. Maintain MARKET WEIGHT on the sector.
GREATER CHINA Economics Trade Exports rebounded in August but outlook remains challenging. Sector IT Hardware Maintain preference for the more defensive AI-device plays as uncertainty remains high. Maintain OVERWEIGHT. INDONESIA Update Bank Mandiri (BMRI IJ/HOLD/Rp7,250/Target: Rp7,760) 7M24: Strong ...
GREATER CHINA Results BYD Electronic (285 HK/BUY/HK$27.65/Target: HK$42.50) 1H24: Results missed on margins. Expect peak season to bolster profitability in 2H24. China Feihe (6186 HK/BUY/HK$4.04/Target: HK$5.22) 1H24: Steady profit growth; accelerated revenue expansion in 2H24. China Longyuan Power (916 HK/HOLD/HK$6.16/Target: HK$6.10) 1H24: Below expectations; power generation dragged by low wind speed. ...
AP reported a net profit of Bt1.27b in 2Q24 (-18% yoy, +26% qoq). The results were in line with expectations. We expect 3Q24 earnings to continue improving qoq, driven by the continued transfers of low-rise backlogs and a newly completed condo project. We revised down earnings by 4-14% for 2024-26 to reflect downside risks in presales and transfers. However, we still like AP for its fundamentals. AP is trading at an undemanding valuation. Maintain BUY. Target price: Bt11.30.
KEY HIGHLIGHTS Results Amata Corporation (AMATA TB/BUY/Bt23.50/Target: Bt30.00) 2Q24: Earnings below expectations; positive earnings outlook in 2H24. AP Thailand (AP TB/BUY/Bt7.85/Target: Bt11.30) 2Q24: Results within expectations; expect 3Q24 earnings to improve qoq. Bangkok Expressway and Metro (BEM TB/BUY/Bt7.75/Target: Bt11.60) 2Q24: Earnings in line. Banpu PCL (BANPU TB/HOLD/Bt4.60/Target: Bt5.00) ...
GREATER CHINA Economics Money Supply Weak demand for transactional funds and medium- to long-term loans. Results Foxconn Industrial Internet (601138 CH/BUY/Rmb20.78/Target: Rmb30.00) 2Q24: Solid progress in AI business; margin misses due to product mix changes. Sino Biopharmaceutical (1177 HK/BUY/HK$2.95/Target: HK$4.00) 1H24: Results beat; expects double-digit revenue and earnings growth in 2024. INDONESIA Update In...
AP reported strong presales of Bt14b (+14% yoy, +49% qoq) in 2Q24, marking its thirdhighest quarterly record. 1H24 presales came in at Bt24.1b (+2% yoy), driven by the lowrise and high-rise segments. Earnings in 2Q24 are expected to recover from the previous quarter, supported by strong gross margins and the completion of key projects. Maintain BUY. Target price: Bt13.50.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.